Skip to main content
Premium Trial:

Request an Annual Quote

MorphoSys Expands Antibody Development Deal with Pfizer Three Years

NEW YORK (GenomeWeb News) — MorphoSys today said it has expanded by three years its collaboration with drug giant Pfizer for the development of antibody therapeutics.
 
The agreement builds upon a deal struck in 2003 scheduled to end in 2008. The new deal extends the collaboration to 2011 and includes a one-off payment from Pfizer, MorphoSys said.
 
Under the agreement, MorphoSys, based in Martinsried, Germany, will use its HuCAL Gold human combinatory antibody library to generate therapeutic antibodies against targets supplied by Pfizer, which Pfizer will then take to preclinical and clinical trials.
 
The collaboration currently involves five active antibody programs, but MorphoSys said that number could double under the new agreement.
 
MorphoSys also said the agreement offers potential royalties and milestone payments from resulting product sales.
 
Financial terms of the agreement were not released.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.